Potential therapeutic opportunities targeting them to reinstate AIS include a CCAR1 functional mimetic CFM-4 having in vivo efficacy in human nonsmall cell lung cancer treatment [68], and a dual-specific antibody against death receptors 4 and 5 upstream of FADD showing proapoptotic activity in human breast, ovarian, and colon cancer xenografts [69]. Here, CCAR1 is linked to lung cancer.